MX2023006176A - Nuevos derivados de indazol acetileno. - Google Patents

Nuevos derivados de indazol acetileno.

Info

Publication number
MX2023006176A
MX2023006176A MX2023006176A MX2023006176A MX2023006176A MX 2023006176 A MX2023006176 A MX 2023006176A MX 2023006176 A MX2023006176 A MX 2023006176A MX 2023006176 A MX2023006176 A MX 2023006176A MX 2023006176 A MX2023006176 A MX 2023006176A
Authority
MX
Mexico
Prior art keywords
acetylene derivatives
new indazole
indazole
new
formula
Prior art date
Application number
MX2023006176A
Other languages
English (en)
Spanish (es)
Inventor
Cosimo Dolente
Sander Ulrike Obst
Annick Goergler
Georg Jaeschke
Antonio Ricci
David Stephen Hewings
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2023006176A publication Critical patent/MX2023006176A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2023006176A 2020-12-01 2021-11-29 Nuevos derivados de indazol acetileno. MX2023006176A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20210859 2020-12-01
PCT/EP2021/083279 WO2022117477A1 (en) 2020-12-01 2021-11-29 New indazole acetylene derivatives

Publications (1)

Publication Number Publication Date
MX2023006176A true MX2023006176A (es) 2023-06-08

Family

ID=73654642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006176A MX2023006176A (es) 2020-12-01 2021-11-29 Nuevos derivados de indazol acetileno.

Country Status (16)

Country Link
US (1) US12686682B2 (enExample)
EP (1) EP4255908A1 (enExample)
JP (1) JP7840327B2 (enExample)
KR (1) KR20230116799A (enExample)
CN (1) CN116490182A (enExample)
AR (1) AR124170A1 (enExample)
AU (1) AU2021393722A1 (enExample)
CA (1) CA3197659A1 (enExample)
CL (1) CL2023001440A1 (enExample)
CO (1) CO2023006912A2 (enExample)
CR (1) CR20230218A (enExample)
IL (1) IL303064A (enExample)
MX (1) MX2023006176A (enExample)
PE (1) PE20240099A1 (enExample)
TW (1) TWI915460B (enExample)
WO (1) WO2022117477A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2961187T3 (es) 2019-06-21 2024-03-08 Hoffmann La Roche Inhibidor de EGFR para el tratamiento del cáncer
CN116507328A (zh) 2020-12-01 2023-07-28 豪夫迈·罗氏有限公司 新的吲唑衍生物
EP4522113A1 (en) * 2022-05-13 2025-03-19 F. Hoffmann-La Roche AG Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1252693A1 (zh) 2015-06-30 2019-05-31 Dana Farber Cancer Institute, Inc. Egfr抑制剂及其使用方法
TW201834651A (zh) 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (en) 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
ES2927480T3 (es) 2017-06-02 2022-11-07 Hoffmann La Roche Compuestos de isoindolina-acetileno para el tratamiento del cáncer
IL279800B2 (en) 2018-06-29 2024-02-01 Hoffmann La Roche Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use
ES2961187T3 (es) 2019-06-21 2024-03-08 Hoffmann La Roche Inhibidor de EGFR para el tratamiento del cáncer
US20220315577A1 (en) 2019-06-21 2022-10-06 Hoffmann-La Roche Inc. New egfr inhibitors
TW202115073A (zh) 2019-06-21 2021-04-16 瑞士商赫孚孟拉羅股份公司 新穎的egfr抑制劑
AR120799A1 (es) 2019-12-20 2022-03-16 Hoffmann La Roche 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr
AR120800A1 (es) 2019-12-20 2022-03-16 Hoffmann La Roche Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr
CN116507328A (zh) 2020-12-01 2023-07-28 豪夫迈·罗氏有限公司 新的吲唑衍生物
JP7798887B2 (ja) 2020-12-01 2026-01-14 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
JP2025515833A (ja) 2022-05-13 2025-05-20 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
EP4522113A1 (en) 2022-05-13 2025-03-19 F. Hoffmann-La Roche AG Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
WO2022117477A1 (en) 2022-06-09
IL303064A (en) 2023-07-01
TW202237611A (zh) 2022-10-01
KR20230116799A (ko) 2023-08-04
US20240002390A1 (en) 2024-01-04
CO2023006912A2 (es) 2023-06-09
CR20230218A (es) 2023-07-07
CL2023001440A1 (es) 2023-12-01
PE20240099A1 (es) 2024-01-18
AU2021393722A1 (en) 2023-04-13
CA3197659A1 (en) 2022-06-09
TWI915460B (zh) 2026-02-21
EP4255908A1 (en) 2023-10-11
US12686682B2 (en) 2026-07-21
JP7840327B2 (ja) 2026-04-03
JP2023550902A (ja) 2023-12-06
CN116490182A (zh) 2023-07-25
AR124170A1 (es) 2023-02-22

Similar Documents

Publication Publication Date Title
CO2022008968A2 (es) Nuevos derivados de metilquinazolinona
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
CO2023006912A2 (es) Nuevos derivados de indazol acetileno
AR121226A1 (es) Compuestos y usos de estos
MX2025004220A (es) Compuestos triciclicos y sus usos
AR115949A1 (es) Compuestos heterocíclicos
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR066972A1 (es) Derivados azapeptidicos
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
CR20240203A (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
CL2022001353A1 (es) Inhibidores de egfr
PE20200333A1 (es) Compuestos y metodos para tratar infecciones bacterianas
CL2023002908A1 (es) Compuestos heterocíclicos de arilo como bloqueadores del canal agitador de potasio kv1.3
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
AR131472A1 (es) Moduladores de nampt
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
CO2025010725A2 (es) Compuestos moduladores de receptores de dopamina d3/d2
PE20201148A1 (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
JOP20240119A1 (ar) مشتقات نافثيريدينون لمعالجة مرض أو اضطراب
MX2024008745A (es) Compuesto derivado de 1,3-benzodioxol y composicion farmaceutica que comprende el mismo.